12/23
11:20 am
mrna
U.S. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Market Research: Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2030 [Yahoo! Finance]
Low
Report
U.S. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Market Research: Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2030 [Yahoo! Finance]
12/23
09:17 am
mrna
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait? [Yahoo! Finance]
Low
Report
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait? [Yahoo! Finance]
12/18
08:09 am
mrna
Moderna, Inc. (NASDAQ: MRNA) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.
Medium
Report
Moderna, Inc. (NASDAQ: MRNA) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.
12/10
08:00 am
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $41.00 price target on the stock.
Medium
Report
Moderna, Inc. (NASDAQ: MRNA) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $41.00 price target on the stock.
11/26
09:43 am
mrna
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $59.00 to $45.00. They now have an "underweight" rating on the stock.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $59.00 to $45.00. They now have an "underweight" rating on the stock.
11/26
07:22 am
mrna
Moderna, Inc. (MRNA): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
Medium
Report
Moderna, Inc. (MRNA): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
11/25
07:00 am
mrna
Moderna to Present at Upcoming Conferences in December 2024
Medium
Report
Moderna to Present at Upcoming Conferences in December 2024
11/22
10:23 am
mrna
Moderna, Inc. (MRNA) Jefferies London Healthcare Conference (Transcript) [Seeking Alpha]
Low
Report
Moderna, Inc. (MRNA) Jefferies London Healthcare Conference (Transcript) [Seeking Alpha]
11/19
08:30 am
mrna
Moderna, Inc. (NASDAQ: MRNA) is now covered by analysts at Berenberg Bank. They set a "hold" rating and a $42.00 price target on the stock.
Medium
Report
Moderna, Inc. (NASDAQ: MRNA) is now covered by analysts at Berenberg Bank. They set a "hold" rating and a $42.00 price target on the stock.
11/19
06:22 am
mrna
Moderna, Inc. (NASDAQ: MRNA) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating.
Medium
Report
Moderna, Inc. (NASDAQ: MRNA) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating.
11/18
12:36 pm
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $69.00 price target on the stock, down previously from $115.00.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $69.00 price target on the stock, down previously from $115.00.
11/18
08:07 am
mrna
Moderna, Inc. (NASDAQ: MRNA) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $58.00 price target on the stock.
Medium
Report
Moderna, Inc. (NASDAQ: MRNA) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $58.00 price target on the stock.
11/15
05:43 pm
mrna
Moderna, Inc. (MRNA) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript) [Seeking Alpha]
Medium
Report
Moderna, Inc. (MRNA) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript) [Seeking Alpha]
11/12
08:15 am
mrna
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
Low
Report
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
11/8
02:32 pm
mrna
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Barclays PLC from $125.00 to $111.00. They now have an "overweight" rating on the stock.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Barclays PLC from $125.00 to $111.00. They now have an "overweight" rating on the stock.
11/8
10:59 am
mrna
Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Low
Report
Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
11/8
08:46 am
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/8
07:30 am
mrna
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Medium
Report
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
11/8
02:21 am
mrna
Moderna Inc (MRNA) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... [Yahoo! Finance]
Medium
Report
Moderna Inc (MRNA) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... [Yahoo! Finance]
11/7
03:38 pm
mrna
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View [Yahoo! Finance]
Low
Report
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View [Yahoo! Finance]
11/7
11:47 am
mrna
Ahead of Fed Decision, Big Earnings Wins for Forgotten Names [Yahoo! Finance]
Medium
Report
Ahead of Fed Decision, Big Earnings Wins for Forgotten Names [Yahoo! Finance]
11/7
06:30 am
mrna
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
High
Report
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/4
10:47 am
mrna
Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures [Yahoo! Finance]
Low
Report
Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures [Yahoo! Finance]
11/4
10:31 am
mrna
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $70.00 to $59.00. They now have an "underweight" rating on the stock.
Medium
Report
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $70.00 to $59.00. They now have an "underweight" rating on the stock.
11/4
09:05 am
mrna
Pfizer struggles to find new revenue sources as vaccine sales fade, but here's why investors shouldn't shy away from its stock [Globe and Mail, The (Toronto, Canada)]
Low
Report
Pfizer struggles to find new revenue sources as vaccine sales fade, but here's why investors shouldn't shy away from its stock [Globe and Mail, The (Toronto, Canada)]